1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Indaptus Therapeutics agreed on September 8, 2026 to sell 20,338,974 shares of common stock to purchasers in a private placement for aggregate gross proceeds of about $24.0 million before offering expenses. The company plans to use the proceeds for working capital, research and development, and general corporate purposes, possibly including early-stage work on a neurotechnology device for sleep-related conditions. The shares are unregistered, and the company must later file a resale registration statement, which could add shares to the market.
Shares sold: 20,338,974 shares of common stock at a price equal to the Nasdaq Minimum Price plus $0.015 per share
Gross proceeds: approximately $24.0 million before offering expenses
Closing: subject to customary conditions, no later than the fifteenth business day after September 8, 2026
Shares were sold under Section 4(a)(2) and/or Regulation S and are subject to transfer restrictions
Group 1 Automotive agreed to sell $1.25 billion of senior unsecured notes in two tranches, due 2032 and 2035, with expected net proceeds of about $1,236.0 million and closing expected on September 22, 2026. The company plans to use the proceeds, with cash on hand, to fund its pending purchase of dealership assets and related real estate from Hennessy Automobile Companies, and the filing says the 2032 notes must be redeemed if that acquisition is not completed by the outside date.
$625.0 million of 6.250% senior notes due 2032 and $625.0 million of 6.625% senior notes due 2035, sold at par
Expected net proceeds of approximately $1,236.0 million; closing expected September 22, 2026
If the Hennessy Acquisition is not consummated by January 6, 2027, or any extended date, the 2032 notes must be redeemed at 100% of issue price plus accrued interest
Affiliates of certain initial purchasers are lenders under the company's revolving credit facility and will receive a portion of the net proceeds
PAVmed Inc. signed a Sales Agreement with A.G.P./Alliance Global Partners that lets it sell common stock through the agent from time to time, up to $9,400,000 of shares under its current prospectus supplement. The company says it plans to use net proceeds for working capital and general corporate purposes, and the sales would dilute existing shareholders.
Maximum offering under the current prospectus supplement is $9,400,000 of common stock.
The agent's commission is 3.0% of aggregate gross sales prices, plus legal cost reimbursements of up to $65,000 at signing.
Shares are offered under a Form S-3 shelf registration declared effective April 15, 2025, with a prospectus supplement dated September 9, 2026.
Either party may terminate the agreement on ten business days' written notice.
Plains All American Pipeline priced $700 million of 6.75% Series A and $800 million of 7.00% Series B junior subordinated notes due 2056, expected to close September 14, 2026. The company plans to use the proceeds, with cash on hand and commercial paper, to redeem all of its outstanding Series A and Series B preferred units. The filing replaces preferred units with junior debt but does not state the effect on earnings or distributions.
$700 million of 6.75% Series A and $800 million of 7.00% Series B junior subordinated notes due 2056 priced, with closing expected September 14, 2026
Proceeds, cash on hand and commercial paper to redeem all 58,411,908 Series A preferred units and all 800,000 Series B preferred units
Series A units redeemed at $28.875 per unit (110% of $26.25 par) on or about September 14, 2026; Series B at $1,000 par on or about October 9, 2026
Principal Financial Group and two subsidiaries entered into an amended and restated five-year credit facility with Wells Fargo as administrative agent, refinancing the company's existing revolving facility dated October 18, 2022. The facility allows borrowing of up to $900 million, with a commitment termination date of September 9, 2031, and no borrowings are currently outstanding; this is a routine financing update with no new debt drawn.
Facility allows borrowing of up to $900 million, expandable to a maximum of $1.3 billion subject to conditions
Commitment termination date of September 9, 2031, with up to two 1-year extensions
No borrowings outstanding under the facility as of filing
Financial covenants include minimum Statutory Surplus of $2,885,208,297 and Total Debt to Total Capital ratio not exceeding 35%
Enbridge agreed with an underwriting syndicate led by RBC Capital Markets and CIBC Capital Markets to sell 38.9 million common shares at CDN$66.85 each, for gross proceeds of CDN$2.6 billion. The company plans to use the net proceeds to partially fund announced acquisitions and to create financial flexibility for future growth, which would add new shares outstanding for existing holders.
Offering of 38,900,000 common shares at CDN$66.85 per share, for aggregate gross proceeds of CDN$2.6 billion
Offering expected to close on or about September 14, 2026
Underwriters hold an option for up to 15% more shares, which would bring gross proceeds to about CDN$3.0 billion if fully exercised
Net proceeds intended to partially fund announced acquisitions and provide financial flexibility
On September 9, 2026, CenterPoint Energy and its subsidiaries Houston Electric, CERC and SIGECO replaced their existing revolving credit facilities with four new five-year facilities totaling $4.6 billion in aggregate commitments. The company reported that no termination penalties were incurred on the earlier facilities. The filing describes a refinancing of existing credit capacity rather than a change in the company's earnings or guidance.
CenterPoint Energy parent replaced its $2.4 billion facility, dated December 6, 2022, with a new $2.2 billion facility, with a request option for increases up to $2.5 billion.
Houston Electric replaced a $300 million facility with a new $1.0 billion facility; CERC replaced $1.05 billion with $1.1 billion; SIGECO replaced $250 million with $300 million.
The parent facility limits debt to consolidated capitalization to 67.5%, temporarily raised to 70% after certain natural disaster certifications.
JPMorgan Chase Bank, N.A. serves as administrative agent for the parent facility and will serve as agent for the other three facilities.
Horizon Funding II, a wholly owned subsidiary of Horizon Technology Finance Corporation (HRZN), signed amendments on September 2, 2026 to its securitization financing documents, including a second supplemental indenture and a second amended and restated note funding agreement. The filing says the amendments extend the Legal Final Payment Date to December 10, 2035, but it does not disclose the size of the notes or any change in interest cost, so the financial effect for shareholders is not quantified.
Amendments dated September 2, 2026 cover the indenture, note funding agreement and sale and servicing agreement for Horizon Funding II, LLC.
The Legal Final Payment Date is extended to December 10, 2035.
The filing references the original indenture dated June 21, 2024 and prior amendments dated May 23, 2025.
The 8-K was signed by CEO Michael P. Balkin on September 9, 2026.
National Rural Utilities Cooperative Finance Corporation (CFC) said it will redeem all $400 million of its 5.60% Medium-Term Notes due 2026 on October 13, 2026, at par plus accrued interest. The company said the redemption is intended to reduce interest expense and will be paid with cash on hand.
Redemption of all $400 million of 5.60% Medium-Term Notes due 2026 (CUSIP 63743HFK3) on October 13, 2026
Notes redeemed at par plus accrued interest
Stated purpose is to reduce interest expense; funded with cash on hand
Notice to investors was provided on September 8, 2026
On September 7, 2026, Lexaria Bioscience Corp. agreed with holders of existing warrants covering 453,969 shares to exercise them immediately at a reduced $12.92 per share, for expected gross proceeds of about $5.9 million before fees and expenses. In return, the company will issue new unregistered Series A and Series B warrants, each covering 453,969 shares at $12.67, and must file a resale registration statement for the underlying shares. The cash is intended for working capital and general corporate purposes, but the reduced exercise price and new warrants add potential future share issuance for existing shareholders.
Expected gross proceeds of about $5.9 million from the warrant exercises, before placement agent fees and offering expenses; closing expected September 9, 2026.
Existing warrants issued in 2024 and 2025 had original exercise prices from $17.85 to $45.90 per share; holders exercised at $12.92.
New Series A warrants (five-year term) and Series B warrants (18-month term) each cover 453,969 shares at $12.67 per share.
H.C. Wainwright & Co. is placement agent, paid a fee of 7% of gross proceeds, and received warrants for 15,889 shares at $16.15.
Limbach Holdings and subsidiaries entered a five-year, $300.0 million credit agreement with PNC Bank, National Association, maturing September 9, 2031. The new facility replaces the company's existing $125.0 million Wintrust revolving credit facility, which was terminated after about $118.1 million of principal was repaid from PNC proceeds, with no early termination penalties reported.
Facility totals up to $300.0 million: $200.0 million revolver, $50.0 million term loan and $50.0 million delayed draw term loan
Loans priced at Base Rate plus 0.50% to 1.50%, or Term SOFR plus 1.50% to 2.50%, based on net leverage
Financial covenants require maximum net leverage of 3.00 to 1.00 and minimum fixed charge coverage of 1.15 to 1.00
About $7.0 million of existing letters of credit remain outstanding under the former Wintrust agreement until they expire, with latest expiry in April 2027
Tenon Medical said it repaid in full its original issue discount senior convertible promissory notes, with an aggregate principal balance of approximately $5.16 million, ahead of their September 11, 2026 maturity date. The company says the repayment removes the potential for the notes to convert into common stock at a discount to market prices, which it describes as reducing potential dilution for shareholders.
Notes with approximately $5.16 million aggregate principal balance repaid in full
Notes were issued on March 11, 2026 and were due September 11, 2026
Company states the repayment reduces potential dilution from discounted conversion into common stock
Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics, to develop next-generation menin inhibitors for diabetes and other cardiometabolic diseases. On September 8, 2026, Caspian completed a $50.0 million Series A preferred stock financing, in which Kura invested $4.3 million and which left Kura holding about 49.2% of Caspian's outstanding capital stock.
Caspian completed a $50.0 million private Series A preferred stock financing on September 8, 2026.
Kura invested $4.3 million and held about 49.2% of Caspian's outstanding capital stock after the financing.
Kura contributed rights to menin inhibitors, including KO-7246, to Caspian for Caspian common stock and reimbursement of up to $1.5 million in maintenance costs.
Kura will provide research, development and administrative services to Caspian under a services agreement with a one-year initial term.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.